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ABSTRACT
Objective: To determine the magnitude of potentially causal relationships among vascular risk fac-
tors (VRFs), large-artery atheromatous disease (LAD), and cerebral white matter hyperintensities
(WMH) in 2 prospective cohorts.
Methods: We assessed VRFs (history and measured variables), LAD (in carotid, coronary, and leg
arteries), and WMH (on structural MRI, visual scores and volume) in: (a) community-dwelling older
subjects of the Lothian Birth Cohort 1936, and (b) patients with recent nondisabling stroke. We
analyzed correlations, developed structural equation models, and performed mediation analysis
to test interrelationships among VRFs, LAD, and WMH.
Results: In subjects of the Lothian Birth Cohort 1936 (n 5 881, mean age 72.5 years [SD 60.7
years], 49% with hypertension, 33% with moderate/severe WMH), VRFs explained 70% of the
LAD variance but only 1.4% to 2% of WMH variance, of which hypertension explained the most.
In stroke patients (n 5 257, mean age 74 years [SD 611.6 years], 61% hypertensive, 43%
moderate/severe WMH), VRFs explained only 0.1% of WMH variance. There was no direct
association between LAD and WMH in either sample. The results were the same for all WMH
measures used.
Conclusions: The small effect of VRFs and LAD on WMH suggests that WMH have a large
“nonvascular,” nonatheromatous etiology. VRF modification, although important, may be limited
in preventing WMH and their stroke and dementia consequences. Investigation of, and inter-
ventions against, other suspected small-vessel disease mechanisms should be addressed.
Neurology® 2014;82:1–8
GLOSSARY
ABPI 5 ankle-brachial pressure index; BP 5 blood pressure; eGFR 5 estimated glomerular filtration rate; HbA1c 5 hemo-
globin A1c; IMT 5 intima-media thickness; LAD 5 large-artery atheromatous disease; LBC1936 5 Lothian Birth Cohort
1936; MSS 5 Mild Stroke Study; RCT 5 randomized controlled trial; SVD 5 small-vessel disease; VRF 5 vascular risk
factor; WMH 5 white matter hyperintensity.
White matter hyperintensities (WMH) are a major component of cerebral small-vessel disease
(SVD) and substantially increase the risk of dementia, stroke,1 and physical disability.2 Despite
this considerable clinical and societal impact, the causes of SVD and WMH are poorly
understood.3
WMH are associated with several common vascular risk factors (VRFs) offering potentially
modifiable targets: hypertension,4–9 diabetes, hypercholesterolemia, smoking, and possibly
carotid stenosis.10 Hypertension was associated withWMH progression6–9; better blood pressure
(BP) control delayed WMH progression in observational studies9 and in one randomized con-
trolled trial (RCT).11 However, there are anomalies: in larger RCTs, antihypertensive treatment
did not prevent WMH progression,12 intensive BP reduction did not prevent recurrent lacunar
stroke,13 and the associations between BP and WMH were often weak14 or disappeared with
correction for age and baseline WMH, both strong predictors of WMH progression.15–17 Statins
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did not prevent WMH progression,18 and dual
(vs mono) antiplatelet therapy increased death
in patients with lacunar stroke without pre-
venting recurrence.19,20
These discrepancies question the strength
of associations among VRFs, atheroma, and
SVD, contrasting with the effectiveness of
antihypertensive, antiplatelet drugs and statins
in preventing atheromatous ischemic stroke.
We hypothesized that if WMH mainly occur
secondary to VRFs or are a “small-vessel”
form of atheroma, then either of these or both
should explain most WMH variance. We
determined how much WMH variability was
attributable to VRFs and/or large-artery athero-
matous disease (LAD) in 2 cohorts.
METHODS The derivation cohort is the Lothian Birth Cohort
1936 (LBC1936),21 community-dwelling older subjects born in
1936, now being studied to determine lifetime influences on aging.
The replication cohort is a prospective study of patients with recent
nondisabling ischemic stroke, the Mild Stroke Study (MSS).22
The LBC1936 subjects were aged 71 to 74 years (mean 72.5,
SD 0.72) at assessment. TheMSS patients were aged 34 to 95 years
(mean 74, SD 11.62). In both groups, we obtainedmedical history,
physiologic measurements, blood samples, brain MRI, and carotid
Doppler ultrasound imaging (full details in references 21–23).
We recorded hypertension, diabetes, hypercholesterolemia
(all medically diagnosed and/or on relevant drugs), ischemic heart
disease, peripheral vascular disease or other circulatory problems
(all diagnosed by general practitioner or hospital doctor), and
smoking (current vs stopped .1 year ago or never smoked).
History of stroke was also collected in the LBC1936 cohort. All
MSS participants had an index stroke (on clinical criteria and
MRI with diffusion imaging22) as a study entry criterion.
In the LBC1936 cohort, we measured systolic and diastolic
BP, each 3 times sitting and standing during a 4-hour Clinical
Research Facility assessment. We also measured the following:
ankle-brachial pressure index (ABPI), carotid intima-media thick-
ness (IMT) in the common carotid artery and carotid bulb on
both sides (mean of 3 measures by Framingham24 and by manual
caliper measurements), carotid flow velocities, maximum stenosis
affecting the internal carotid artery/bulb/common carotid
artery,25 hemoglobin A1c (HbA1c), plasma total cholesterol and
Figure 1 LBC1936 cohort: Diagram of measurement models for the VRF and LAD constructs
Standardized loadings and residual correlations are shown. Numbers adjacent to paths may be squared to obtain the shared
variance between adjacent variables. Double-headed arrows are correlations; single-headed arrows are hypothesized causal
pathways. The convention used represents manifest (measured) variables as rectangles and constructed variables (VRFs or
LAD) as circles. Model fit parameters are shown adjacent to the constructed variable: a nonsignificant x2 is a sign of a well-
fittingmodel; theMaxMI (which indicates the degree of greatest local strainwithin themodel in terms of a potential reduction in
model x2); the CFI ($0.90 indicates acceptable fit); and the RMSEA (,0.06 indicates acceptable fit). CFI 5 comparative fit
index; HbA1c5 hemoglobin A1c; LAD5 large-artery atheromatous disease; LBC19365 Lothian Birth Cohort 1936; MaxMI5
maximum modification index; RMSEA 5 root mean square error of approximation; VRF 5 vascular risk factor.
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albumin, urinary albumin, microalbuminuria, and estimated glo-
merular filtration rate (eGFR). All measures were performed
blinded to all other data. In the MSS subjects, we also performed
echocardiography where clinically indicated and measured all of the
above (including carotid Doppler ultrasound on the same scanner
with the same operators) except ABPI, HbA1c, IMT, eGFR, mi-
croalbuminuria, and albumin, and only one BP reading was avail-
able, but we had more detailed history and medical examination.
All LBC1936 andMSS subjects underwent brain MRI on the
same 1.5-tesla GE Signa Horizon HDx clinical scanner (General
Electric, Milwaukee, WI) and had T1-, T2-, and T2*-weighted
and fluid-attenuated inversion recovery axial whole-brain imag-
ing.22,23 A neuroradiologist, trained in WMH rating, quantified
the WMH on fluid-attenuated inversion recovery using the
Fazekas score.26 A second neuroradiologist cross-checked a ran-
dom 20% of ratings, uncertain ratings, and cases with suspected
infarct. In the LBC1936, we also measured WMH volumes in
cubic millimeters using a validated multispectral image processing
method (http://sourceforge.net/projects/bric1936/) that maps
combinations of magnetic resonance sequences to the red-green
color space for tissue segmentation.23,27 We checked all seg-
mented images visually for accuracy blinded to all clinical details,
manually removed any errors, and masked all imaging-detected
infarcts to avoid confounding the WMH volumes.28
Standard protocol approvals, registrations, and patient
consents. Both studies were approved by Lothian Research Eth-
ics (LBC1936 REC 07/MRE00/58; MSS 2002/8/64) and
LBC1936 additionally by the Scottish Multicentre (MREC/01/
0/56) Research Ethics. Written informed consent was obtained
from all participants.
Analytical approach. We used all available data, because the
pattern of missing values was acceptably random (e.g., more
LBC1936 subjects completed carotid than brain imaging).
WMH were not associated with carotid disease on right or left
sides separately so we combined sides. We used the average of sit-
ting BPs after exploring multiple individual measures of systolic
and diastolic and mean BPs at sitting and standing positions.
We examined correlation matrices and excluded variables with
no/low correlation from further analysis, e.g., eGFR and microal-
buminuria. Where both variables were continuous, we used the
Pearson correlation coefficient; dichotomous, we used tetrachoric
correlation; and 1 dichotomous/1 continuous, we used biserial
correlation. The p values for the latter 2 correlations were deter-
mined from their variance and standard error.29
We used structural equation models to test the contribution of
VRFs and LAD to the WMH burden. Such models are described
using path diagrams, e.g., figures 1 and 2, where the square boxes
represent measured observations, e.g., BP. Each circle represents a
“latent construct,” e.g., LAD or VRFs, that underlies a combination
of correlated individual measured variables. Single-headed arrows
represent simple regression relationships, and double-headed arrows
represent correlations. In structural equation models, it is conven-
tional to divide the modeling into 2 parts. Measurement models are
used to check whether the variance shared by several measured
variables constitutes an underlying latent trait. Structural models
are used to test hypothesized relationships among latent and mea-
sured variables. Figure 1 shows measurement models for LAD and
VRFs, where each circle represents an underlying latent construct
that is a weighted combination of the correlated measured variables.
Figure 2 shows structural models of relationships between these
latent constructs of LAD, VRFs, and WMH. The models shown
in figure 2, A and B, test the hypothesis that the association between
LAD and WMH may be explained by common association with
VRFs. Under this hypothesis, we expected the total association
between LAD and WMH (figure 2A) to be reduced when VRFs
were controlled in both variables (figure 2B). The models shown in
figure 2, C and D, test the hypothesis that any direct relationship
between VRFs and WMH (figure 2C) is mediated by LAD (figure
2D; details in appendix e-1 on the Neurology® Web site at
Neurology.org).
In the LBC1936, we grouped the measured variables into
those that represented (1) VRFs, (2) LAD in the arteries supply-
ing the brain, heart, or legs, and (3) WMH measures. VRFs
included history variables (hypertension, diabetes, hypercholes-
terolemia, smoking) and measured variables (BP, HBA1c, and
plasma cholesterol). LAD included history variables (ischemic
heart disease, peripheral vascular disease, other circulatory prob-
lems) and measured variables (ABPI, carotid stenosis, and IMT;
figure 1).24 The variables were grouped based on medical knowl-
edge, correlations, a scree plot of the principal components, and
the exploratory factor analysis.30 For WMH, because deep and
periventricular WMH were highly correlated (r 5 0.53, p ,
0.001), we combined them into a summed Fazekas score. We
also tested WMH volume as a percent of intracranial volume and
of brain parenchymal volume. The correlation between the 2
percentage WMH scores was 0.998, and between the Fazekas
scores and each of the 2 percentage scores was 0.760 and
0.765. The Fazekas score was ordinal, and both percentage meas-
ures were continuous variables. Both were positively skewed and
zero-inflated (less than 18% of the sample were zeros), and these
measures were treated as censored from below at zero using Tobit
regression.
Figure 2 Structural models in the LBC1936
(A) This model is the total association between LAD and WMH. (B) Hierarchical association
with VRFs controlled. (C) Total effect of VRFs on WMH. (D) The mediation model (see the
text). Standardized regression coefficients (parameter weights) are shown adjacent to each
path. Each arrow is directed from a predictor variable to the outcome variable. In model B,
the 0.828 indicates that approximately 70% of the variance in LAD is explained by VRFs
and the 0.111 indicates that approximately 2% of the variance in WMH is explained by
VRFs. The 0.292 and 0.984 adjacent to the lateral arrows in model B indicate the variance
that is unexplained by VRFs on LAD and WMH, respectively. The estimates shown in the fig-
ure are for WMHmeasured using combined periventricular and deep Fazekas scores. The es-
timates for the model using other WMHmeasures are shown in table 2. R2 is the WMHmodel
R2 value; s2 is the residual variance. LAD 5 large-artery atheromatous disease; LBC1936 5
Lothian Birth Cohort 1936; VRF5 vascular risk factor; WMH5white matter hyperintensity.
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Table 1 LBC1936 and MSS subjects’ demographics and prevalence of features indicating large-artery
disease, vascular risk factors, and white matter hyperintensities
Variable LBC1936 Descriptive MSS Descriptive
Sample no. 861 257
Age, mean (SD) 72 (0.7) 74 (12)
Sex
Female 446 (52) 88 (34)
Male 415 (48) 169 (66)
Large-artery disease
Intima-media thickness, mm (common
carotid artery)a
[0.4, 0.8] 228 (28)
[0.7, 1.1] 521 (64)
[1.1, 1.4] 56 (7)
[1.4, 1.7] 10 (1)
Stenosis (%, NASCET, left carotid)a [1, 24] 656 (81) [1, 24] 203 (79)
[25, 49] 146 (18) [25, 49] 44 (17)
[50, 74] 10 (1) [50, 74] 3 (1)
[75, 100] 3 (0.4) [75, 100] 7 (3)
Stenosis (%, NASCET, right carotid)a [1, 24] 627 (77) [1, 24] 213 (83)
[25, 50] 170 (21) [25, 50] 33 (13)
[50, 75] 14 (2) [50, 75] 8 (3)
[75, 100] 4 (1) [75, 100] 3 (1)
Ischemic heart disease
No 613 (71) 206 (80)
Yes 248 (29) 52 (20)
Peripheral vascular disease
Pain in the leg when walking or in bed at night
No 496 (58) 247 (96)
Yes 365 (42) 11 (4)
Ankle-brachial pressure indexa [0.54, 0.87] 63 (8)
[0.87, 1.19] 509 (68)
[1.19, 1.52] 167 (22)
[1.52, 1.85] 12 (7)
Vascular risk factors
Hypertension
No 439 (51) 100 (39)
Yes 422 (49) 158 (61)
Diabetes
No 767 (89) 221 (86)
Yes 94 (11) 37 (14)
Hypercholesterolemia
No 508 (59) 166 (65)
Yes 353 (41) 90 (35)
Plasma cholesterol, mmol/La [2, 4] 226 (27) [2, 4] 26 (15)
[4, 6] 452 (55) [4, 5] 88 (50)
[6, 8] 141 (17) [5, 7] 46 (26)
[8, 10] 8 (1) [7, 8] 15 (9)
Continued
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We performed a similar analysis in the MSS cohort by testing
groupings of VRF and LAD measured variables and WMH
(figure e-1).
We used Mplus version 6.131 to fit the measurement and
structural models of regression relationships between the variables
simultaneously. We estimated model parameters by weighted
least-squares and assessed the indirect effect in the mediation
model (model D) using a bias-corrected bootstrapped confidence
interval derived by Monte Carlo sampling.32,33 We controlled for
sex in all variables but not age (adjusting for age had negligible
effect and all subjects were of very similar ages, SD5 0.71 years).
We examined estimates of factor loadings (unstandardized, stan-
dardized, and squared multiple correlation coefficient) and several
indices of model fit: the comparative fit index ($0.90 indicates
acceptable fit), the root mean square error of approximation
(,0.06 indicates acceptable fit), and the maximum modification
index (indicates the degree of greatest local strain within the
model in terms of a potential reduction in model x2).
RESULTS Primary analysis. In the LBC1936, 861
subjects (415, 48% male) of mean age 72.5 years
(SD 0.7, range 71–74 years) had full clinical
assessment and carotid imaging; 681 subjects com-
pleted brain imaging and provided WMH scores and
volumes. Of the 861, 422 (49%) had hypertension,
94 (11%) had diabetes, 248 (29%) had ischemic
heart disease, the median carotid stenosis was 20%,
and 33% had moderate or severe WMH scores (table
1).
Multivariate measurement models to derive the
VRF and LAD latent variables (figure 1) indicate that
all observed variables contributed significantly to the
latent variable (p , 0.05) except for smoking (p 5
0.66), which nonetheless we included in the VRF
model. The models all fitted the data well (figure 1).
Structural models (figure 2) show the standardized
estimates for WMH measured using Fazekas scores.
Without accounting for VRFs (figure 2A), there was a
small but reliable shared variance of approximately
4% and 6% between LAD and WMH, depending
on which WMH measure was used (all 3 WMH
measures were statistically significant; table 2).
Table 1 Continued
Variable LBC1936 Descriptive MSS Descriptive
Plasma HbA1C (n subjects) Blood glucose, mmol/L
[4, 6] 440 (58) [3, 8] 129 (86)
[6, 7] 275 (36) [8, 13] 11 (7)
[7, 8] 41 (5) [13, 17] 8 (5)
[8, 10] 8 (1) [17, 22] 2 (1)
Smoker Ex or never smoked 789 (92) No 107 (43)
Yes 72 (8) Yes 144 (57)
Diastolic BP, mm Hga [50, 66] 92 (11) [37, 62] 15 (6)
[66, 82] 474 (55) [62, 86] 123 (51)
[82, 98] 276 (32) [86, 111] 97 (40)
[98, 114] 19 (2) [111, 135] 5 (2)
Systolic BP, mm Hga [82, 117] 38 (4) [98, 130] 52 (22)
[117, 151] 446 (52) [130, 162] 121 (50)
[151, 186] 351 (41) [162, 194] 53 (22)
[186, 220] 26 (3) [194, 226] 14 (6)
White matter hyperintensities R 1 L combined Right Left
Fazekas score periventricular 0 23 (4) 9 (4) 9 (4)
1 444 (65) 132 (52) 133 (52)
2 171 (25) 65 (26) 64 (25)
3 43 (6) 48 (19) 48 (19)
Fazekas score (deep white matter overall) 0 111 (16) 40 (16) 43 (17)
1 430 (63) 140 (55) 136 (54)
2 120 (18) 36 (14) 37 (15)
3 20 (3) 38 (15) 38 (15)
Abbreviations: BP 5 blood pressure; HbA1c 5 hemoglobin A1c; LBC1936 5 Lothian Birth Cohort 1936; MSS 5 Mild
Stroke Study; NASCET 5 North American Symptomatic Carotid Endarterectomy Trial.
Data are counts (%) unless otherwise indicated; numbers in square brackets are quartile boundaries.
a The numbers reported are the counts and percentages in 4 intervals, the thresholds chosen to give 4 equal intervals of
the observed range of each variable.
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However, when VRFs were accounted for (figure
2B), the total association between LAD and WMH
became smaller and nonsignificant with all 3 WMH
measures (table 2). Therefore, the small association
between LAD and WMH seen in model A before
VRFs were considered was mainly explained by VRFs
acting through LAD. In addition, VRFs were a far
stronger predictor of LAD than of WMH, accounting
for approximately 70% of variation in LAD burden
(standardized parameter weight 0.828) but less than
2% of variation in WMH (standardized parameter
weight 0.111).
The mediation model (figure 2, C and D) indi-
cates that the standardized total effect of VRFs (figure
2C, effect c in table e-1), explained no more than a
small (2%) but significant variance in WMH. Explor-
ing the effect of LAD as a mediating variable for VRFs
(figure 2D, appendix e-1, and table 1) did not explain
the missing variance in WMH, instead emphasizing
the presence of large influences onWMH that are not
captured in history or concurrent measures of VRFs
or LAD.
The magnitude of individual VRF contributions to
WMH (table e-2, a and b) were all small; e.g., the larg-
est individual contributions to WMH variance were
hypertension (2.4%) and smoking (0.89%).
Replication in the stroke cohort. The MSS patients
(n 5 257) had similar mean age although a wider
range (74.2, SD611.6 years, range 34–95 years) than
the LBC1936, but more MSS patients were hyperten-
sive (61%), smoked (57.4%), and had moderate to
severe WMH scores (44.3% periventricular, 29.6%
deep; table 1, figure e-1). A combined hierarchical
factor analysis model showed that VRFs explained
35% of LAD variance (standardized parameter weight
0.594) but only 0.1% of WMH variance (standard-
ized parameter weight 20.033), with hypertension
again being the strongest individual factor.
DISCUSSION WMH are a huge health problem,
doubling the risk of dementia and trebling the risk
of stroke. We were surprised to find that although
VRFs explained 70% of the burden of LAD and
hypertension was the strongest single risk factor for
WMH, all common VRFs combined failed to account
for 98% of WMH. Furthermore, there was no direct
association between LAD and WMH; any apparent
association was through a coassociation with VRFs.
We found the same results in 2 separate cohorts, one
community-dwelling, the other with stroke,
regardless of how WMH were assessed. The
mediation model highlighted the absence of key
factors to account for most of the WMH variance.
The proportion of subjects with hypertension in
the LBC1936 (49%) was similar to the proportion
in other similar aging studies,34 and the proportion
MSS patients (61%) was similar to stroke patients
elsewhere (55%–66%).34 Hypertension was the
strongest risk factor for WMH in LBC1936, as in
other observational studies.6–9 Consistent with our
results, large increments in diastolic BP (e.g., 10
mm Hg above the mean baseline diastolic BP of 83
6 11 mm Hg) were associated with small differences
inWMH in cross-sectional studies (e.g., 1.21% larger
WMH volume)4; large increments in systolic BP (20
mm Hg) were associated with small increases in
WMH volume (2.5 mL) at follow-up.8 The associa-
tion between WMH and hypertension applied only
to diastolic5 or systolic BP,8 indicating variation in
strength of association.35 Most studies adjusted for
age, but not for baseline WMH, a strong predictor
of WMH progression,16,36 although baseline adjust-
ment should be handled cautiously because it may
distort estimates of change in longitudinal studies.37
Others also noted a lack of independent association
between WMH and BP in patients with stroke.15
The modest VRF effect is supported by RCTs.
Antihypertensive treatment had no effect in the large
PRoFESS (Prevention Regimen for Effectively Avoid-
ing Second Strokes) MRI substudy (n5 771) after an
average of 28 months12: insufficient BP lowering was
blamed for not preventing WMH progression,
but the average systolic/diastolic BP reduction in
PRoFESS (3.0/1.3 mm Hg) was identical to the sys-
tolic/diastolic BP increment (3.0/2.0 mm Hg) blamed
for WMH progression over only 14 months of follow-
up in a 584-patient observational cohort.14 Intensive vs
usual antihypertensive treatment did not significantly
reduce recurrent lacunar stroke.13 In RCTs of other
Table 2 Results for hierarchical (structural) models A and B in figure 2
WMH measure
Model A Model B
b1 b2 R12 R22r r
Fazekas score (combined) 0.202 (p , 0.01) 0.135 (p 5 0.28) 0.828 (p , 0.01) 0.111 (p 5 0.03) 0.708 0.016
WMH as % of intracranial volume 0.238 (p , 0.01) 0.208 (p 5 0.13) 0.830 (p , 0.01) 0.114 (p 5 0.02) 0.711 0.016
WMH as % of brain tissue 0.249 (p , 0.01) 0.220 (p 5 0.11) 0.830 (p , 0.01) 0.118 (p 5 0.02) 0.711 0.016
Abbreviation: LAD 5 large-artery atheromatous disease; VRF 5 vascular risk factor; WMH 5 white matter hyperintensity.
Model A is total association. Model B is hierarchical with VRFs controlled. r is the correlation between LAD and WMH. b1 and b2 are standardized regression
coefficients: LAD on VRFs and WMH on VRFs. R12 and R22 are R2 values: LAD on VRFs and WMH on VRFs. Sex is controlled in all variables.
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VRF modifications that reduce adverse outcomes from
LAD, statins had no effect in preventing WMH pro-
gression,18 and dual vs mono antiplatelet therapy
caused excess hemorrhage and death without reducing
recurrent stroke in patients with lacunar stroke.19,20
However, data on lipids and WMH are lacking and
should be addressed in further studies.
Our study strengths include the large sample (total
n 5 1,118), a development (n 5 861) and replication
(n5 257) cohort, and robust statistics. The narrow age
range of the LBC1936 subjects minimized the powerful
confounding effect of age on WMH, LAD, and VRFs.
The results were the same in theMSS patients whose ages
spanned 6 decades and had more vascular disease. The
LBC1936 subjects are all white Caucasian, minimizing
any influence of ethnic differences on VRFs. We have no
reason to think that our subjects are unrepresentative of
other Caucasian cohorts (Scotland has one of the highest
vascular disease rates in the world). A third of the
LBC1936 and approximately 40% of MSS patients
had moderate to severe WMH. We found the same
results for WMH assessed by visual rating and volume.
We carefully excluded infarcts from the WMH volume:
inadvertent inclusion of infarcts in “WMH volume”may
have inflated associations among VRFs, LAD, and
WMH previously.28
The study had limitations. We lacked continuous
BP monitoring but used the average of 3 systolic and
diastolic BP readings obtained over 4 hours at sitting
positions by trained technicians. Most other studies
of WMH and BP have not used continuous BP meas-
ures. Perhaps our subjects were too old: BP decreases
between middle and old age38; WMH may be more
closely associated with long-standing elevated BP
from middle age.5 However, BP measured 3 years
earlier at approximately age 69 was very similar; our
“history of hypertension” captured prior hypertension
and was the strongest risk factor. Age 72 is not par-
ticularly “old.” The stroke cohort including much
younger subjects produced the same result. Future
studies could test other BP parameters. Adding other
imaging markers of SVD might increase the sensitiv-
ity for detecting causal relationships. Some variables
were missing but without evidence of bias and we
used all available data. The high prevalence of peri-
pheral vascular disease in the LBC1936 may represent
overreporting but is counterbalanced by the objective
measure of peripheral vascular disease with the ABPI
and by the MSS where history and examination were
very detailed and the same associations were found.
Our results suggest that WMH have a large “non-
vascular” component. The remaining unexplained 98%
ofWMH variance will hinder advances in prevention of
dementia, stroke,1 and physical dependency2 in aging.
Treating hypertension and diabetes, lowering choles-
terol, and stopping smoking are important. Lifestyles
that minimize vascular risk should be encouraged.
Other modifiable risk factors (e.g., vitamins),39 dietary
factors (e.g., salt), inflammation, and other nonvascular
contributing mechanisms should be sought.
AUTHOR CONTRIBUTIONS
J.M. Wardlaw, M. Allerhand, I. Deary, F. Doubal: study concept and design.
F. Doubal, A. Gow, I. Deary, J. Starr, M. Bastin, M. Dennis, J.M. Wardlaw:
acquisition of data. M. Allerhand, M. Valdez Hernandez, Z. Morris, F. Doubal,
M. Dennis, I. Deary, J. Starr, J.M. Wardlaw: analysis and interpretation.
I. Deary, M. Dennis, F. Doubal, M. Allerhand, M. Valdez Hernandez,
A. Gow, J.M. Wardlaw: critical revision of the manuscript for important
intellectual content. J.M. Wardlaw, I. Deary: study supervision.
ACKNOWLEDGMENT
The authors thank the radiographers at the Brain Research Imaging Cen-
tre; Elizabeth Eadie and Avril Thomas, ultrasonographers at the Depart-
ment of Neuroradiology, Edinburgh (www.bric.ed.ac.uk); the nurses of
the Wellcome Trust Clinical Research Facility, Edinburgh (www.wtcrf.ed.
ac.uk); P. Davies, J. Corley, A. Pattie, and R. Henderson for coordination,
data collection, and entry for LBC1936; and the staff at Lothian Health
Board and at the SCRE Centre, University of Glasgow.
STUDY FUNDING
The initial recruitment and testing of the LBC1936 was supported by
Research Into Ageing: the subsequent imaging and related data collection used
here was supported by Age UK (The Disconnected Mind project; the Sidney
de Haan Award for Vascular Dementia) and the Medical Research Council
(G1001245 and 82800). The MSS was funded by the Chief Scientist Office
of the Scottish Executive (CZB/4/281) and the Wellcome Trust (075611).
The Brain Research Imaging Centre is supported by the SINAPSE Collabo-
ration (www.sinapse.ac.uk) funded by the Scottish Funding Council and
Chief Scientist Office and NHS Lothian Research and Development
Office. The work was partly undertaken within the University of
Edinburgh Centre for Cognitive Aging and Cognitive Epidemiology
(G0700704/84698, http://www.ccace.ed.ac.uk/), part of the cross council
Lifelong Health and Wellbeing Initiative. Funding from the BBSRC,
EPSRC, ESRC, and MRC is gratefully acknowledged. The study funders
had no role in study design, data collection, analysis, interpretation, or
writing of the report.
DISCLOSURE
The authors report no disclosures relevant to the manuscript. Go to
Neurology.org for full disclosures.
Received July 11, 2013. Accepted in final form December 29, 2013.
REFERENCES
1. Debette S, Markus HS. The clinical importance of white
matter hyperintensities on brain magnetic resonance imag-
ing: systematic review and meta-analysis. BMJ 2010;341:
c3666.
2. Baezner H, Blahak C, Poggesi A, et al. Association of gait
and balance disorders with age-related white matter
changes: the LADIS study. Neurology 2008;70:935–942.
3. Wardlaw JM, Smith C, Dichgans M. Mechanisms of spo-
radic cerebral small vessel disease: insights from neuroi-
maging. Lancet Neurol 2013;12:483–497.
4. Marcus J, Gardener H, Rundek T, et al. Baseline and
longitudinal increases in diastolic blood pressure are
associated with greater white matter hyperintensity vol-
ume: the Northern Manhattan Study. Stroke 2011;42:
2639–2641.
5. Guo X, Pantoni L, Simoni M, et al. Blood pressure com-
ponents and changes in relation to white matter lesions: a
32-year prospective population study. Hypertension 2009;
54:57–62.
Neurology 82 April 15, 2014 7
ª 2014 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
6. Dufouil C, De Kersaint-Gilly A, Besancon V, et al. Longi-
tudinal study of blood pressure and white matter hyperinten-
sities: the EVA MRI Cohort. Neurology 2001;56:921–926.
7. de Leeuw FE, de Groot JC, Oudkerk M, et al. Hyperten-
sion and cerebral white matter lesions in a prospective
cohort study. Brain 2002;125:765–772.
8. Gottesman RF, Coresh J, Catellier DJ, et al. Blood pres-
sure and white-matter disease progression in a biethnic
cohort. Atherosclerosis Risk in Communities (ARIC)
Study. Stroke 2010;41:3–8.
9. Godin O, Tzourio C, Maillard P, Mazoyer B, Dufouil C.
Antihypertensive treatment and change in blood pressure
are associated with the progression of white matter lesion
volumes: the Three-City (3C)-Dijon Magnetic Resonance
Imaging Study. Circulation 2011;123:266–273.
10. de Leeuw FE, de Groot JC, Bots ML, et al. Carotid ath-
erosclerosis and cerebral white matter lesions in a popula-
tion based magnetic resonance imaging study. J Neurol
2000;247:291–296.
11. Dufouil C, Chalmers J, Coskun O, et al. Effects of blood
pressure lowering on cerebral white matter hyperintensities
in patients with stroke: the PROGRESS (Perindopril Pro-
tection against Recurrent Stroke Study) Magnetic Resonance
Imaging Substudy. Circulation 2005;112:1644–1650.
12. Weber R, Weimar C, Blatchford J, et al. Telmisartan on
top of antihypertensive treatment does not prevent pro-
gression of cerebral white matter lesions in the prevention
regimen for effectively avoiding second strokes (PRoFESS)
MRI substudy. Stroke 2012;43:2336–2342.
13. Benavente OR, McClure LA, Coffey CS, et al. The sec-
ondary prevention of small subcortical strokes (SPS3)
Trial: results of the blood pressure intervention. Lancet
2013;382:507–515.
14. Liu W, Liu R, Sun W, et al. Different impacts of blood
pressure variability on the progression of cerebral micro-
bleeds and white matter lesions. Stroke 2012;43:2916–2922.
15. Rost NS, Rahman R, Sonni S, et al. Determinants of white
matter hyperintensity volume in patients with acute ische-
mic stroke. J Stroke Cerebrovasc Dis 2010;19:230–235.
16. Gouw AA, van der Flier WM, Fazekas F, et al. Progression
of white matter hyperintensities and incidence of new
lacunes over a 3-year period: the Leukoaraiosis and Disa-
bility Study. Stroke 2008;39:1414–1420.
17. Wardlaw JM, Doubal FN, Valdes-Hernandez MC, et al.
Blood-brain barrier permeability and long term clinical
and imaging outcomes in cerebral small vessel disease.
Stroke 2013;44:525–527.
18. ten Dam VH, van den Heuvel DM, van Buchem MA,
et al. Effect of pravastatin on cerebral infarcts and white
matter lesions. Neurology 2005;64:1807–1809.
19. SPS3 Investigators. Effects of clopidogrel added to aspirin
in patients with recent lacunar stroke. N Engl J Med 2012;
367:817–825.
20. Palacio S, Hart RG, Pearce LA, Benavente OR. Effect of
addition of clopidogrel to aspirin on mortality: systematic
review of randomized trials. Stroke 2012;43:2157–2162.
21. Deary IJ, Gow AJ, Taylor MD, et al. The Lothian Birth
Cohort 1936: a study to examine influences on cognitive
ageing from age 11 to age 70 and beyond. BMC Geriatr
2007;7:28.
22. Doubal FN, MacGillivray TJ, Hokke PE, Dhillon B,
Dennis MS, Wardlaw JM. Differences in retinal vessels
support a distinct vasculopathy causing lacunar stroke.
Neurology 2009;72:1773–1778.
23. Wardlaw JM, Bastin ME, Valdes Hernandez MC, et al.
Brain aging, cognition in youth and old age and vascular
disease in the Lothian Birth Cohort 1936: rationale, design
and methodology of the imaging protocol. Int J Stroke
2011;6:547–559.
24. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M.
Prediction of clinical cardiovascular events with carotid
intima-media thickness: a systematic review and meta-
analysis. Circulation 2007;115:459–467.
25. Wardlaw JM, Lewis S. Carotid stenosis measurement on
colour Doppler ultrasound: agreement of ECST, NAS-
CET and CCA methods applied to ultrasound with
intra-arterial angiographic stenosis measurement. Eur J
Radiol 2005;56:205–211.
26. Fazekas F, Chawluk JB, Alavi A, Hurtig HI,
Zimmerman RA. MR signal abnormalities at 1.5T in Alz-
heimer’s dementia and normal aging. AJR Am J Roent-
genol 1987;149:351–356.
27. Valdes Hernandez MC, Ferguson KJ, Chappell FM,
Wardlaw JM. New multispectral MRI data fusion tech-
nique for white matter lesion segmentation: method and com-
parison with thresholding in FLAIR images. Eur Radiol 2010;
20:1684–1691.
28. Wang X, Valdes Hernandez MC, Doubal F,
Chappell FM, Wardlaw JM. How much do focal infarcts
distort white matter lesions and global cerebral atrophy
measures? Cerebrovasc Dis 2012;34:336–342.
29. Fox J, Weisberg S. An R Companion to Applied Regres-
sion, 2nd ed. Thousand Oaks: Sage Publications; 2011.
30. Child D. The Essentials of Factor Analysis, 3rd ed. London:
Continuum International Publishing Group; 2006.
31. Muthén LK, Muthén BO. Mplus User’s Guide, 6th ed.
Los Angeles: Muthén & Muthén; 2010.
32. Preacher KJ, Hayes AF. SPSS and SAS procedures for
estimating indirect effects in simple mediation models.
Behav Res Methods Instrum Comput 2004;36:717–731.
33. Preacher KJ, Hayes AF. Asymptotic and resampling strate-
gies for assessing and comparing indirect effects in multiple
mediator models. Behav Res Methods 2008;40:879–891.
34. O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for
ischaemic and intracerebral haemorrhagic stroke in 22
countries (the INTERSTROKE Study): a case-control
study. Lancet 2010;376:112–123.
35. van Dijk EJ, Breteler MMB, Schmidt R, et al. The asso-
ciation between blood pressure, hypertension, and cerebral
white matter lesions: Cardiovascular Determinants of
Dementia Study. Hypertension 2004;44:625–630.
36. van Dijk EJ, Prins ND, Vrooman HA, Hofman A,
Koudstaal PJ, Breteler MM. Progression of cerebral small
vessel disease in relation to risk factors and cognitive
consequences: Rotterdam Scan Study. Stroke 2008;39:
2712–2719.
37. Glymour MM, Weuve J, Berkman LF, Kawachi I,
Robins JM. When is baseline adjustment useful in analyses
of change? An example with education and cognitive
change. Am J Epidemiol 2005;162:267–278.
38. Wills AK, Lawlor DA, Matthews FE, et al. Life course
trajectories of systolic blood pressure using longitudinal
data from eight UK cohorts. PLoS Med 2011;8:e1000440.
39. Cavalieri M, Schmidt R, Chen C, et al. B vitamins and
magnetic resonance imaging–detected ischemic brain le-
sions in patients with recent transient ischemic attack or
stroke: the VITAmins TO Prevent Stroke (VITATOPS)
MRI-substudy. Stroke 2012;43:3266–3270.
8 Neurology 82 April 15, 2014
ª 2014 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
DOI 10.1212/WNL.0000000000000312
 published online March 12, 2014Neurology 
Joanna M. Wardlaw, Michael Allerhand, Fergus N. Doubal, et al. 
hyperintensities
Vascular risk factors, large-artery atheroma, and brain white matter
This information is current as of March 12, 2014
Services
Updated Information &
 00000000312.full.html
http://www.neurology.org/content/early/2014/03/12/WNL.00000
including high resolution figures, can be found at:
Supplementary Material
 00000000312.DC1.html
http://www.neurology.org/content/suppl/2014/03/12/WNL.00000
Supplementary material can be found at: 
Subspecialty Collections
 http://www.neurology.org//cgi/collection/vascular_dementia
Vascular dementia
 http://www.neurology.org//cgi/collection/stroke_prevention
Stroke prevention
 iology
http://www.neurology.org//cgi/collection/risk_factors_in_epidem
Risk factors in epidemiology
 http://www.neurology.org//cgi/collection/mri
MRI
following collection(s): 
This article, along with others on similar topics, appears in the
  
Permissions & Licensing
 http://www.neurology.org/misc/about.xhtml#permissions
or in its entirety can be found online at:
Information about reproducing this article in parts (figures,tables)
  
Reprints
 http://www.neurology.org/misc/addir.xhtml#reprintsus
Information about ordering reprints can be found online:
